China To Tighten Control Over Stimulants
This article was originally published in PharmAsia News
In China's continuous crack down on illegal production and trading of stimulants, China's State FDA, State Administration for Industry & Commerce, Ministry of Industry & Information Technology and Ministry of Public Security have jointly announced that effective June 19, all chemical companies should not produce or deal with prohibited substances in the catalog of stimulants without permission. Online advertising and sales of such products, including protein assimilation preparations and peptide hormones, are also strictly prohibited. China will further intensify inspection work: eight ministries including the Ministry of Health and SFDA will inspect the stimulant management of the six Olympics host cities from late June to early July; investigation and confirmation of contraband will lead to heavy prosecution; and telephone number and email address will be publicized for informants. (Click here for more - Chinese Language)
You may also be interested in...
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.
In the second segment of a two-part article on transparency provisions for the new EU clinical trial portal, a senior Merck executive explains how the company will ensure that commercially sensitive information and personal data in its clinical trial applications are not made public.
The UK's Advertising Standards Authority will closely monitor the marketing communications of dietary supplements e-tailer Health Solutions after it failed to provide a substantive response to health claims regulation breaches.